It has been argued that Barrett’s Oesophagus is the most important identifiable risk factor in oesophageal adenocarcinoma (gullet cancer). This can occur as a result of chronic acid reflux, causing cell changes in the oesophagus which in some cases can progress to cancer. Chronic heartburn with more than 3 to 4 episodes per week is a risk for Barrett’s Oesophagus and until recently, Barrett’s Oesophagus could only be detected by endoscopy.
The Cytosponge is a capsule containing a soft, compressed mesh sponge, attached to a fine string. It can detect changes in the cells lining the oesophagus and diagnose Barrett’s Oesophagus** more simply and comfortably compared to endoscopy
The Cytosponge cell* collection device is a new innovative way to detect Barrett’s Oesophagus in at risk patients and is an option for those at higher risk of Barrett’s Oesophagus, leading to early stage treatment and cancer prevention.
How does the Cytosponge cell work?
The capsule is swallowed by the patient and after several minutes, a small, soft sponge emerges from the capsule. The sponge is then gently removed by pulling on the string in a smooth, quick motion. As the sponge is pulled up and out it collects cells from the lining of the oesophagus. The whole process takes less than 10 minutes.
Professor Grant Fullarton is a Consultant General Surgeon at Ross Hall Hospital who specialises on gastroenterology.
Cytosponge cell device is covered by most insurance companies or can be on a self-pay basis. Please check your cover details with your insurer directly.*
Please be aware that there are a range of other treatment options available for Barrett's Oesophahus and BMI does not endorse or recommend any particular products or treatments.**
12th June 2019